SK Biopharmaceuticals Co., Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘SK Biopharmaceuticals Co., Ltd. – Product Pipeline Review – 2016’, provides an overview of the SK Biopharmaceuticals Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by SK Biopharmaceuticals Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of SK Biopharmaceuticals Co., Ltd.

The report provides overview of SK Biopharmaceuticals Co., Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses SK Biopharmaceuticals Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features SK Biopharmaceuticals Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate SK Biopharmaceuticals Co., Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for SK Biopharmaceuticals Co., Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding SK Biopharmaceuticals Co., Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

SK Biopharmaceuticals Co., Ltd. Snapshot 6

SK Biopharmaceuticals Co., Ltd. Overview 6

Key Information 6

Key Facts 6

SK Biopharmaceuticals Co., Ltd. - Research and Development Overview 7

Key Therapeutic Areas 7

SK Biopharmaceuticals Co., Ltd. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

SK Biopharmaceuticals Co., Ltd. - Pipeline Products Glance 12

SK Biopharmaceuticals Co., Ltd. - Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

SK Biopharmaceuticals Co., Ltd. - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

SK Biopharmaceuticals Co., Ltd. - Early Stage Pipeline Products 15

IND/CTA Filed Products/Combination Treatment Modalities 15

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

SK Biopharmaceuticals Co., Ltd. - Drug Profiles 18

SKL-N05 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

YKP-3089 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

relenopride hydrochloride 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

carisbamate 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

SKL-15508 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

SKL-A4R 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

SKL-PD 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

SKL-PSY 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

N-2 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

SKL-16036 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

SKL-DEP 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

SKL-G 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecule for Multiple Sclerosis 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecule for Neuropathic Pain 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecule for Tauopathies and Alzheimer's Disease 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

SK Biopharmaceuticals Co., Ltd. - Pipeline Analysis 37

SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Target 37

SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Route of Administration 39

SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Molecule Type 40

SK Biopharmaceuticals Co., Ltd. - Pipeline Products by Mechanism of Action 41

SK Biopharmaceuticals Co., Ltd. - Recent Pipeline Updates 42

SK Biopharmaceuticals Co., Ltd. - Dormant Projects 45

SK Biopharmaceuticals Co., Ltd. - Discontinued Pipeline Products 46

Discontinued Pipeline Product Profiles 46

carisbamate 46

SK Biopharmaceuticals Co., Ltd. - Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

SK Biopharmaceuticals Co., Ltd., Key Information 6

SK Biopharmaceuticals Co., Ltd., Key Facts 6

SK Biopharmaceuticals Co., Ltd. – Pipeline by Indication, 2016 8

SK Biopharmaceuticals Co., Ltd. – Pipeline by Stage of Development, 2016 10

SK Biopharmaceuticals Co., Ltd. – Monotherapy Products in Pipeline, 2016 11

SK Biopharmaceuticals Co., Ltd. – Phase III, 2016 12

SK Biopharmaceuticals Co., Ltd. – Phase II, 2016 13

SK Biopharmaceuticals Co., Ltd. – Phase I, 2016 14

SK Biopharmaceuticals Co., Ltd. – IND/CTA Filed, 2016 15

SK Biopharmaceuticals Co., Ltd. – Preclinical, 2016 16

SK Biopharmaceuticals Co., Ltd. – Discovery, 2016 17

SK Biopharmaceuticals Co., Ltd. – Pipeline by Target, 2016 37

SK Biopharmaceuticals Co., Ltd. – Pipeline by Route of Administration, 2016 39

SK Biopharmaceuticals Co., Ltd. – Pipeline by Molecule Type, 2016 40

SK Biopharmaceuticals Co., Ltd. – Pipeline Products by Mechanism of Action, 2016 41

SK Biopharmaceuticals Co., Ltd. – Recent Pipeline Updates, 2016 42

SK Biopharmaceuticals Co., Ltd. – Dormant Developmental Projects,2016 45

SK Biopharmaceuticals Co., Ltd. – Discontinued Pipeline Products, 2016 46

SK Biopharmaceuticals Co., Ltd., Other Locations 47

SK Biopharmaceuticals Co., Ltd., Subsidiaries 47

List of Figures

List of Figures

SK Biopharmaceuticals Co., Ltd. – Pipeline by Top 10 Indication, 2016 8

SK Biopharmaceuticals Co., Ltd. – Pipeline by Stage of Development, 2016 10

SK Biopharmaceuticals Co., Ltd. – Monotherapy Products in Pipeline, 2016 11

SK Biopharmaceuticals Co., Ltd. – Pipeline by Top 10 Target, 2016 37

SK Biopharmaceuticals Co., Ltd. – Pipeline by Route of Administration, 2016 39

SK Biopharmaceuticals Co., Ltd. – Pipeline by Molecule Type, 2016 40

SK Biopharmaceuticals Co., Ltd. – Pipeline Products by Top 10 Mechanism of Action, 2016 41

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports